1. VENTILATOR ASSOCIATED INJURIES,COMPLICATIONS AND INFECTIONS
Moderator:Dr.B.Kaur
Speaker:Dr.Ashish

2. Ventilator-associated lung injury
Components
BAROTRAUMA
VOLUTRAUMA
ATELECTOTRAUMA
BIOTRAUMA
OXYGEN TOXIC EFFECTS

3. Barotrauma
Barotrauma - rupture of alveolus with subsequent entry of air into pleural space (pneumothorax) and/or tracking or air along the vascular bundle to mediastinum (pneumomediastinum).
Large tidal volumes and elevated peak inspiratory and plateau pressures are risk factors.

4. Barotrauma
Studies in patients with ARDS demonstrated that severity of underlying lung pathology is a better predictor of barotrauma than observed peak inspiratory pressure.

5. Barotrauma
The I:E ratio can be adjusted by increasing inspiratory flow rate, by decreasing tidal volume, and by decreasing ventilatory rate.
Attention to I:E ratio is important to prevent barotrauma in patients with obstructive airway disease (eg, asthma, chronic obstructive pulmonary disease).

6. Volutrauma Volutrauma - local overdistention of normal alveoli.
Volutrauma has gained recognition over last 2 decades d/t importance of lung protection ventilation with low tidal volumes of 6–8 mL/kg.

7. Volutrauma
When a mechanical ventilation breath is forced into patient - positive pressure tends to follow path of least resistance to normal or relatively normal alveoli, potentially causing overdistention.
This overdistention l/t inflammatory cascade that augments or perpetuates the initial lung injury, causing additional damage to previously unaffected alveoli.

8. Volutrauma
The increased local inflammation lowers the patient's potential to recover from ARDS.
The inflammatory cascade occurs locally and may augment the systemic inflammatory response as well.

9. Volutrauma
Another aspect of volutrauma associated with positive ventilation is the shear force associated with the opening and closing effects on collapsible alveoli.
This has also been linked to worsening the local inflammatory cascade.

10. Volutrauma
PEEP prevents alveoli from totally collapsing at the end of exhalation and may be beneficial in preventing this type of injury.

11. ATLECTOTRAUMA Lung injury a/w repeated recruitment and collapse
Preventable by using level of PEEP greater then lower inflection point of pressure-volume curve.
Also k/a low volume or low end expiratory volume injury

12. BIOTRAUMA
Pulmonary and systemic inflammation caused by release of mediators from lungs subjected to injurious mechanical ventiltion.
Mechanism – MECHANOTRANSDUCTION-physical forces are detected by cells and converted into biochemical signals
Injurious ventilatory strategy are as/w release of proinflammatory mediators like thromboxane B2, platelet activating factor and several cytokines.

13. Oxygen toxicity
Oxygen toxicity is a function of increased FIO2 and its duration of use.
Oxygen toxicity is due to production of oxygen free radicals, such as superoxide anion, hydroxyl radical, and hydrogen peroxide.

14. Oxygen toxicity
Oxygen toxicity can cause a variety of complications ranging from mild tracheobronchitis, absorptive atelectasis, and hypercarbia to diffuse alveolar damage .

15. Oxygen toxicity
No consensus has been established for the level of FIO2 required to cause oxygen toxicity
Use the lowest FIO2 that accomplishes the needed oxygenation.

16. Oxygen toxicity
It is adviced to attain an FIO2 of 60% or less within the first 24 hours of mechanical ventilation.
If necessary, PEEP should be considered a means to improve oxygenation while a safe FIO2 is maintained.

17. Lung Protective Strategy
ARDSNet Study - GOALS
PaO mmhg
T.V– 6 ml/Kg IBW
RR up to 35 to maintain a pH > 7.30,
if <7.15 then HCO3
Plateau Pressure < 30 cm H2O

18. How to set PEEP Use PEEP FIO2 table from ARDSnet study
This table is designed to be appropriate for the average patient, but sometimes PEEP needs to be individualized

19. Ventilator associated pneumonia
Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an Endotracheal tube or Tracheostomy.

20. Ventilator associated pneumonia
Ventilator-associated pneumonia remain important causes of morbidity and mortality despite
advances in antibiotics therapy,
better supportive care modalities,
and use of a wide-range of preventive measures

21. Ventilator associated pneumonia
The exact incidence of VAP is 6 to 20 fold greater than in Non-Ventilated patients.
VAP is associated with a higher crude mortality than other hospital-acquired infections (Level II).

22. How does the lung get infected ?
Sources of pathogens for VAP include
The environment (air, water, equipment,), and
Transfer of microorganisms between the patient and staff or other patients (Level II)
A number of host- and treatment-related factors,
Severity of the patient’s underlying disease,
Prior surgery,
Exposure to antibiotics
Exposure to invasive respiratory devices and equipment. (Level II).

23. How does the lung get infected ?
Aspiration of
oropharyngeal pathogens, or
leakage of secretions around the endotracheal tube
are the primary routes of bacterial entry into the lower respiratory tract (Level II)

24. How does the lung get infected ?
Hematogenous spread from infected intravenous Catheters.
Bacterial translocation from the gastrointestinal tract lumen are uncommon pathogenic mechanisms (Level II)

25. How does the lung get infected ?
Infected bio-film in the endotracheal tube, with subsequent embolization to distal airways, may be important in the pathogenesis of VAP (Level III)
The sinuses may be potential reservoirs of nosocomial pathogens but their contribution is controversial, (Level II)

26. Early & Late VAP Early: < 3 days of mechanical ventilation
Typically community acquired agents
Strep. Pneumoniae
Other Streptococci
MSSA
Late:
> 3 days from initiation of ventilation
Gram negatives
Pseudomonas
Acinetobacter
Klebsiella
MRSA

27. Early vs late VAP
Time of onset of pneumonia is an important variable for the outcomes in patients with VAP .
Early-onset VAP, usually carry a better prognosis, and are more likely to be caused by antibiotic-sensitive bacteria.
Late-onset VAP are likely to be caused by multi-drug resistant (MDR) pathogens, and are associated with increased patient mortality and morbidity.

28. Clinical presentation of VAP
Usually suspected when a patient on mechanical ventilation develops
new pulmonary infiltrates
fever,
leucocytosis
purulent secretions.
Additional indicators maybe
increased Respiratory Rate,
increased minute ventilation,
decreased oxygenation,
or need of higher ventilatory support.

29. Diagnosis of VAP
Diagnosis is DIFFICULT because the clinical signs and x-ray features are non specific.
ONLY 50% OF PATIENTS WITH ALL ABOVE FINDINGS WILL HAVE VAP.

30. CLINICAL PULMONARY INFECTION SCORE: (CPIS)
Points are given for 7 variables
Temperature
WBC Count
PaO2/FiO2
Chest X-ray
Quality of tracheal secretions
Progression of infiltrate
Culture of aspirate
Score >6 is considered suggestive of VAP.
BUT, recent studies have consistently shown low specificity and sensitivity of CPIS.

31. How Do We Diagnose? 2-1-2 Radiographic evidence x 2 consecutive days
New, progressive or persistent infiltrate
Consolidation, opacity, or cavitation
At least 1 of the following:
Fever (> 38 degrees C) with no other recognized cause
Leukopenia (< 4,000 WBC/mm3) or leukocytosis (> 12,000 WBC/mm3)
At least 2 of the following:
New onset of purulent sputum or change in character of secretions
New onset or worsening cough, dyspnea, or tachypnea
Rales or bronchial breath sounds
Worsening gas exchange (↓ sats, P:F ratio < 240, ↑ O2 req.)
Mechanically ventilated (ETT or trache) for > 48 hours

32. MICROBIOLOGY OF LOWER RESPIRATORY TRACT
2 TYPES OF METHODS:
A] BRONCHOSCOPIC METHODS
i) BAL (broncho-alveolar lavage)
ii) PSB (protected specimen brush)
B] NON BRONCHOSCOPIC (blind) METHODS
i) TRACHEO-BRONCHIAL ASPIRATION
ii) mini- BAL

33. BRONCHOSCOPIC METHODS
BAL(Bronchoalveolar lavage)
Involves infusion & aspiration of saline through a flexible fiberoptic bronchoscope that is wedged in a bronchial segment.
use atleast 140 ml saline to maximize yield
> 10 4 CFU/ml are taken as positive.
PSB( Protected specimen brush)
Minimises contamination during bronchoscopy, because the brush is contained in a protective sheath.
> 10 3 CFU/ml are taken as positive.

34. BAL vs PSB PSB is 90% sensitive and 95% specific.
BAL is 80% sensitive and 85% specific.

35. NON-BRONCHOSCOPIC METHODS
TRACHEOBRONCHIAL ASPIRATION
blind method
basically it is the suction of ET secretions
> 10 5 CFU/ml are taken as positive.
Mini BAL
catheter is advanced till resistance is met, then saline is instilled, followed by aspiration of sample.

36. BRONCHOSPIC vs BLIND TECHNIQUES
Evidence suggests that Bronchoscopic sampling and culture methods tend to have higher specificity, but the overall diagnostic accuracy is comparable.
Bronchoscopic methods have failed to show improvement in
mortality,
length of hospital stay, and
duration of mechanical ventilation when compared to blind methods.
It may, however, lead to a narrower antibiotic regimen.

37. The present CONSENSUS is:-
PROVIDED EMPIRICAL ANTIBIOTICS ARE STARTED AT THE TIME OF SUSPICION OF VAP,
EITHER OF THE TWO METHODS CAN BE USED FOR THE DIAGNOSIS.

38. Controversy : Use of Selective decontamination of digestive tract
SDD = use of prophylactic iv and oral antibiotics to sterilize the gut
In low resistance settings, efficacy of SDD is convincing.
In conditions of high antibiotic resistance (like in most Indian ICUs), SDD cant be recommended for prevention of VAP.

39. Modifiable Risk Factors
General prophylaxis.
Effective infection control measures:
staff education,
compliance with hand disinfection,
and isolation to reduce cross-infection with MDR pathogens should be used routinely (Level I)

40. Modifiable Risk Factors
Surveillance of ICU infections,
to identify and quantify endemic and new MDR pathogens, and preparation of
timely data for infection control and
to guide appropriate, antimicrobial therapy in patients with VAP, are recommended (Level II)

41. Intubation and mechanical ventilation.
Intubation and reintubation should be avoided, if possible as it increases the risk of VAP (Level I)
Noninvasive ventilation should be used whenever possible in selected patients with respiratory failure (Level I).
Continuous aspiration of subglottic secretions can reduce the risk of early-onset VAP, and should be used, if available (Level I)

42. Intubation and mechanical ventilation.
Heat–moisture exchangers decrease ventilator circuit colonization, but do not reduce the incidence of VAP.(Level I)
Orotracheal intubation and orogastric tubes are preferred over nasotracheal intubation and nasogastric tubes to prevent nosocomial sinusitis and to reduce the risk of VAP, (Level II)

43. Intubation and mechanical ventilation.
The endotracheal tube cuff pressure should be maintained at greater than 20 cm H2O to prevent leakage of bacterial pathogens around the cuff into the lower respiratory tract (Level II)
Contaminated condensate should be carefully emptied from ventilator circuits and condensate should be prevented from entering the endotracheal tube(Level II)

44. Intubation and Mechanical Ventilation.
Reduced duration of intubation and mechanical ventilation may prevent VAP and can be achieved by protocols to improve the use of sedation and to accelerate weaning (Level II)
Maintaining adequate staffing levels in the ICU can reduce length of stay, improve infection control practices, and reduce duration of mechanical ventilation (Level II)

45. Enteral feeding.
Enteral nutrition is preferred over parenteral nutrition to reduce the risk of complications related to central intravenous catheters and to prevent reflux villous atrophy of the intestinal mucosa that may increase the risk of bacterial translocation (Level I)

46. Body position
Patients should be kept in the semi-recumbent position 30–45°. (Level I)

47. HOB Elevation > 30 Degrees on all Mechanically Ventilated Patients
Contraindications
Hypotension MAP <70
Tachycardia >150
CI <2.0
Central line procedure
Posterior circulation strokes
Cervical spine instability use reverse trendelenburg
Some femoral lines ie: IABP no higher than 30 degrees use reverse trendelenburg
Increased ICP, No higher than 30 degrees avoid hip flexion
Proning

48. Modulation of colonization: Oral antiseptics and antibiotics.
In prior administration of systemic antibiotics there should be increased suspicion of infection with MDR pathogens (Level II)
Prophylactic administration of systemic antibiotics for 24 hours at the time of Intubation is not recommended. (Level I)

49. Modulation of colonization: Oral antiseptics and antibiotics.
Modulation of oro-pharyngeal colonization by the use of oral chlorhexidine. Its routine use is not recommended (Level I)
Use daily interruption or lightening of sedation to avoid constant heavy sedation (Level II)

50. Stress bleeding prophylaxis, transfusion, and hyperglycemia.
There is trend toward reduced VAP with sucralfate, but if stress bleeding prophylaxis is needed either H2 antagonists or sucralfate is acceptable (Level I)
Transfusion of red blood cell and other allogeneic blood products should follow a restricted transfusion trigger policy; (Level I)
Intensive insulin therapy is recommended to maintain serum glucose levels between 80 and 110 mg/dl in ICU patients to reduce nosocomial blood stream infections, duration of mechanical ventilation, ICU stay, morbidity, and mortality (Level I)

51. Recommendations for Diagnosis
Tracheal colonization is common in intubated patients, but in the absence of clinical findings is not a sign of infection, and does not require therapy or diagnostic evaluation (Level II)
All patients with suspected VAP should have blood cultures collected, recognizing that a positive result can indicate the presence of either pneumonia or extrapulmonary infection (Level II)
Samples of lower respiratory tract secretions should be obtained from all patients with suspected VAP, and should be collected before antibiotic changes. (Level II)

52. Recommendations for Diagnosis
For patients with ARDS, it is difficult to demonstrate deterioration of radiographic images.
At least one of the three clinical criteria or hemodynamic instability or deterioration of blood gases, should lead to more diagnostic testing (Level II)

53. Recommendations for the clinical strategy.
A reliable tracheal aspirate Gram stain can be used to direct initial empiric antimicrobial therapy. (Level II)
A negative tracheal aspirate (absence of bacteria or inflammatory cells) in a patient without a recent (within 72 hours) change in antibiotics has a strong negative predictive value (94%) for VAP and should lead to a search for alternative sources of fever (Level II)
The presence of a new or progressive radiographic infiltrate plus at least two of three clinical features (fever, leukocytosis, and purulent secretions) represent the most accurate clinical criteria for starting empiric antibiotic therapy (Level II)
Re-evaluation of the decision to use antibiotics based on the results lower respiratory tract cultures by Day 3 or sooner, is necessary (Level II)

54. Recommendations for initial antibiotic therapy.
Select an initial empiric therapy based on the absence or presence of risk factors for MDR pathogens (Level III). These risk factors include
prolonged duration of hospitalization (>5 days)
admission from a healthcare-related facility
recent prolonged antibiotic therapy (Level II)
Inappropriate therapy is a major risk factor for excess mortality and length of stay for patients with VAP.(Level II).

55. In patients who have recently received an antibiotic, an effort should be made to use an agent from a different antibiotic class (Level III).
Initial empiric therapy should be adapted to local patterns of antibiotic resistance, with each ICU collecting this information and updating it on a regular basis (Level II).

56. Recommendations for Optimal Antibiotic Therapy
Aerosolized antibiotics have not been proven to have value in the therapy of VAP (Level I) .
Combination therapy should be used if patients are likely to be infected with MDR pathogens (Level II).
Combination therapy has enhanced likelihood of initially appropriate empiric therapy (Level I).
If patients receive combination therapy with an aminoglycoside- containing regimen, the aminoglycoside can be stopped after 5–7 days in responding patients (Level III)

57. Recommendations for Optimal Antibiotic Therapy
Efforts should be made to shorten the duration of therapy from the traditional 14 to 21 days to periods as short as 7 days, provided that the etiologic pathogen is not P. aeruginosa, and that the patient has a good clinical response with resolution of clinical features of infection (Level I).

58. Recommendations for selected MDR pathogens.
If Acinetobacter are present, the most active agents are the carbapenems, sulbactam, colistin, and polymyxin. There are no data documenting an improved outcome if these organisms are treated with a combination regimen (Level II)
If Enterobacteriaceae are isolated, then monotherapy with a third-generation cephalosporin should be avoided. The most active agents are the carbapenems (Level II).
Linezolid is an alternative to vancomycin for the treatment of MRSA VAP.(Level III).

59. Recommendations for Assessing Response to Therapy
An assessment of clinical parameters should define the response to therapy. (Level II)
Unless the patient is rapidly deteriorating give Hrs for the therapy to work. (Level III).
Nonresponse to therapy is usually evident by Day 3, (Level II).
A responding patient should have de-escalation of antibiotics, on the basis of culture data (Level II).

60. Recommendations for Assessing Response to Therapy
The non-responding patient should be evaluated for
noninfectious mimics of pneumonia,
unsuspected or drug-resistant organisms,
Extra-pulmonary sites of infection, and
complications of pneumonia and its therapy.
Diagnostic testing should be directed to whichever of these causes is likely (Level III).

61. Four major principles underlie the management of VAP.
Avoid untreated or inadequately treated VAP.
Recognize the variability of bacteriology from
one hospital to another,
specific sites within the hospital, and
from one time period to another,
and use this information to select antibiotic treatment.
Avoid the overuse of antibiotics by focusing on accurate diagnosis.
Apply prevention strategies aimed at modifiable risk factors.

62. Things that DO NOT prevent VAP
Chest physiotherapy
Early tracheostomy.
Change of ventilatory circuits
Change of HME filters
In line suctioning
Prophylactic antibiotics

63. Thank you.